A Transcellular Assay to Assess the P-gp Inhibition in Early Stage of Drug Development

Author(s): Jan-Shiang Taur, Edgar L. Schuck, Nancy Y. Wong

Journal Name: Drug Metabolism Letters

Volume 6 , Issue 4 , 2012

Become EABM
Become Reviewer
Call for Editor


To provide a fast assessment in predicting P-gp-mediated DDI risk during early stage of drug development, a transcellular P-gp inhibition assay using two concentrations is presented in the present study. The efflux ratios of loperamide in the presence of forty-five commercial compounds at two concentrations were measured and compared to that of six concentrations in human P-gp cDNA-expressing LLC-PK1 cells (LLC-MDR1). The inhibition potency calculated from the change on the efflux ratio (ER) and on the net secretory flux (NSF) of loperamide was investigated. The P-gp inhibition potency was defined as potent (IC50 < 1 µM), moderate (1 µM < IC50 < 10 µM), or weak (IC50 > 10 µM). The results using 1 µM and 10 µM of inhibitor concentrations provided the best correlation and are most consistent with those generated from a 6-point approach.

Keywords: Drug-Drug Interaction, IC50, Loperamide, Permeability, P-gp, Transcellular Assay

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 30 June, 2013
Page: [285 - 291]
Pages: 7
DOI: 10.2174/1872312811206040008
Price: $58

Article Metrics

PDF: 25